XON Intrexon Corporation

Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that John Maslowski, Vice President of Scientific Affairs, will present at the World Orphan Drug Congress USA 2015 at 2:30 p.m. EDT on Thursday, April 23 at the Washington D.C. Hilton. Mr. Maslowski's presentation will focus on FCX-007, Fibrocell's novel gene-therapy drug candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a congenital, orphan skin disease caused by the deficiency of the protein collagen VII (COL7). FCX-007 is a gene-modified autologous fibroblast that encodes COL7 and is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.

Fibrocell's presentation will be available on the company's website at http://www.fibrocellscience.com/investors/events-and-presentations/ and archived for 30 days.

World Orphan Drug Congress USA brings together orphan drug stakeholders and global leaders in the rare disease industry to address the latest strategies for product development, commercialization, reimbursement, sustainability, and global market access. This year, Rare Disease Advocacy World is being launched as a complementary program to advance worldwide initiatives in rare disease advocacy. This 3-day forum offers a series of interactive and educational roundtables and workshops, as well as pitch & partner sessions and networking opportunities.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. Fibrocell's gene-therapy orphan drug candidate FCX-007 is in late-stage pre-clinical development for the treatment of RDEB (Recessive Dystrophic Epidermolysis Bullosa). Fibrocell is also developing FCX-013, its gene-therapy orphan drug candidate for the treatment of Linear Scleroderma. In addition, Fibrocell is pursuing medical applications for its proprietary autologous fibroblast technology, azficel-T. Currently, Fibrocell is in a Phase II clinical trial for Dysphonia, a significant voice impairment resulting from vocal cord scarring or atrophy. For more information, visit www.fibrocellscience.com.

CONTACT: Investor Relations Contact:
         
         Karen Casey
         Fibrocell Science
         (484) 713-6133
         kcasey@fibrocellscience.com